Evotec SE announces that today the Chairman of the Supervisory Board, Prof. Dr Wolfgang Plischke, has informed the Company of his decision to resign from his office in the Supervisory Board of Evotec SE effective as of the end of the Annual General Meeting on 15 June 2021 due to personal reasons. Prof. Dr Plischke has been serving in the Supervisory Board as Chairman since 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/chairman-of-the-supervisory-board-of-evotec-to-resign-from-office-effective-as-of-the-end-of-the-annual-general-meeting-on-15-june-2021-6055
Mubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SE
Evotec SE today announced that it resolved on a capital increase from its authorised capital without pre-emptive rights against cash. Evotec will issue a total of 11,478,315 new shares to Mubadala Investment Company and Novo Holdings A/S. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/mubadala-investment-company-and-novo-holdings-as-invest-eur-250-million-in-evotec-se-5980
Evotec SE: Increase of profitability guidance for financial year 2019
Evotec SE today announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company’s financial performance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-se-increase-of-profitability-guidance-for-financial-year-2019-5901
Ad hoc: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough
Evotec SE announced today that the Company has been informed by Bayer about positive Phase IIa results from a study surveying the safety, efficacy and dosage of the compound BAY1817080 in refractory chronic cough. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-positive-phase-ii-data-for-p2x3-antagonist-in-patients-with-refractory-chronic-cough-5835
Ad hoc: Evotec SE to acquire Just Biotherapeutics, Inc.
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”) based in Seattle, WA, USA for up to US$ 90 m (approx. € 81 m; €/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years. The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-se-to-acquire-just-biotherapeutics-inc-5809
Ad hoc: Evotec AG increases its profitability guidance for 2018
Evotec AG today announced that it increases its profitability guidance for the current year after completing its latest financial evaluation. The Company now expects adjusted Group EBITDA to increase by more than 45% (previously: Improve by approx. 30%) in 2018 compared to last year (2017: € 58.4 m). This mainly results from Evotec’s strong business performance leading to increased margin contribution, important scientific milestone achievements in the fourth quarter of 2018 as well as increased other operating income due to e.g. research & development (“R&D”) tax credits in the second half of 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-increases-its-profitability-guidance-for-2018-5759
Ad hoc: Evotec and Celgene enter into strategic oncology partnership
Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-celgene-enter-into-strategic-oncology-partnership-5685
Ad hoc: Evotec AG plans conversion into European Company (SE)
Evotec AG today decided to begin preparations for legal conversion of the Company into a European Company (Societas Europaea, SE). The proposal, which has already been approved by the Supervisory Board, will be put to a vote at this year’s Annual General Meeting on 20 June 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-plans-conversion-into-european-company-se-5663
Ad hoc: Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
Evotec AG today announced that Evotec and Sanofi have entered into exclusive negotiations to accelerate infectious disease research and development through a new open innovation platform led by Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-sanofi-in-exclusive-talks-to-create-an-evotec-led-infectious-disease-open-innovation-rd-platform-5650
Ad hoc: Evotec AG to acquire Aptuit
Evotec AG today announced that it has entered into a definitive agreement with Aptuit Holdings LLC („Aptuit“) under which Evotec will acquire all operational business of Aptuit for $ 300 m (approx. EUR 256 m) to combine the businesses and expand Evotec’s role as leading player in integrated outsourced drug discovery and development solutions. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-to-acquire-aptuit-5